{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:29:42Z","timestamp":1785317382309,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Atrial fibrillation (AF) in critically ill patients (CIP) is associated with worse outcomes and increased mortality in the intensive care unit (ICU). Rhythm control strategies are often unfeasible due to underlying comorbidities, making rate control the preferred initial approach. However, conventional beta-blockers may worsen hemodynamics through negative inotropic effects and peripheral vasodilation. Landiolol, an ultra-short-acting adrenoreceptor antagonist, may offer an alternative due to its high \u03b21-cardioselectivity and minimal blood pressure (BP) impact. This study evaluated the efficacy and feasibility of landiolol in hemodynamically unstable CIP with tachyarrhythmia, used as add-on therapy after failure of standard treatments. Materials and Methods: Ten CIP, admitted for non-postoperative reasons, were prospectively enrolled for landiolol treatment (L-group) in the ICU of Ulm University Heart Center between July and December 2017. The control group contained 41 patients who had received standard therapy without landiolol (NL-group). The primary composite endpoint was defined as heart rate (HR) reduction while maintaining mean arterial pressure (MAP) above 65 mmHg. Results: The most frequent reason for ICU admission was hemodynamic instability related to tachyarrhythmia in patients with cardiogenic or septic shock. At therapy initiation, all patients exhibited a compromised hemodynamic status, with a median MAP of 68.0 (IQR 60.0\u201380.0) mmHg and a median HR of 160.0 (IQR 144.0\u2013176.0) bpm. After a three-hour observation period, no significant differences in BP values were observed between the groups. The primary composite endpoint was achieved at comparable rates in both groups (p = 0.525). However, patients in the L-group achieved a greater reduction in HR compared to those in the NL-group (25.3% vs. 21.9%, p &lt; 0.001). Conclusions: Landiolol achieved more effective HR control than standard therapy without adversely affecting BP stability. These findings suggest that landiolol may be a feasible and effective option for HR control in ICU CIP.<\/jats:p>","DOI":"10.3390\/medicina61091703","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:11:01Z","timestamp":1758269461000},"page":"1703","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted Heart Rate Control with Landiolol in Hemodynamically Unstable, Non-Surgical Intensive Care Unit Patients: A Comparative Study"],"prefix":"10.3390","volume":"61","author":[{"given":"Lyuboslav","family":"Katov","sequence":"first","affiliation":[{"name":"Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gierak","sequence":"additional","affiliation":[{"name":"Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3347-1728","authenticated-orcid":false,"given":"Yannick","family":"Teumer","sequence":"additional","affiliation":[{"name":"Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Diofano","sequence":"additional","affiliation":[{"name":"Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bothner","sequence":"additional","affiliation":[{"name":"Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Rottbauer","sequence":"additional","affiliation":[{"name":"Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-2998","authenticated-orcid":false,"given":"Karolina","family":"Weinmann-Emhardt","sequence":"additional","affiliation":[{"name":"Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0025-7125(05)70313-8","article-title":"Supraventricular Tachycardia","volume":"85","author":"Chauhan","year":"2001","journal-title":"Med. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0885066615599150","article-title":"Prevalence and Course of Atrial Fibrillation in Critically Ill Trauma Patients","volume":"32","author":"Duby","year":"2017","journal-title":"J. Intensive Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.CCM.0000114579.56430.E0","article-title":"Incidence and Risk Factors of Atrial Fibrillation in a Surgical Intensive Care Unit","volume":"32","author":"Seguin","year":"2004","journal-title":"Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.7326\/0003-4819-135-12-200112180-00010","article-title":"Atrial Fibrillation after Cardiac Surgery","volume":"135","author":"Maisel","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zakynthinos, G.E., Tsolaki, V., Xanthopoulos, A., Karavidas, N., Vazgiourakis, V., Bardaka, F., Giamouzis, G., Pantazopoulos, I., and Makris, D. (2024). Prevalence, Risk Factors, and Mortality of New-Onset Atrial Fibrillation in Mechanically Ventilated Critically Ill Patients. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226750"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.chest.2018.03.040","article-title":"Atrial Fibrillation in the ICU","volume":"154","author":"Bosch","year":"2018","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1378\/chest.15-0358","article-title":"Optimizing Atrial Fibrillation Management: From ICU and Beyond","volume":"148","author":"Walkey","year":"2015","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1164\/rccm.201701-0104OC","article-title":"Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling","volume":"196","author":"Reyes","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1004383","DOI":"10.1371\/journal.ppat.1004383","article-title":"Streptococcus Pneumoniae Translocates into the Myocardium and Forms Unique Microlesions That Disrupt Cardiac Function","volume":"10","author":"Brown","year":"2014","journal-title":"PLoS Pathog."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1164\/rccm.201603-0618OC","article-title":"Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study","volume":"195","author":"Klouwenberg","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), with the Special Contribution of the European Heart Rhythm Association (EH-RA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jacep.2022.07.010","article-title":"Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation","volume":"8","author":"Markman","year":"2022","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105080","DOI":"10.1016\/j.nurpra.2024.105080","article-title":"Pill-in-the-Pocket for Paroxysmal Atrial Fibrillation: A Review and Case Study","volume":"20","author":"Hussein","year":"2024","journal-title":"J. Nurse Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2125.1998.t01-1-00768.x","article-title":"Therapeutic Drug Monitoring: Antiarrhythmic Drugs","volume":"46","author":"Campbell","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart Failure and Atrial Fibrillation, Like Fire and Fury","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Koniari, I., Artopoulou, E., Velissaris, D., Mplani, V., Anastasopoulou, M., Kounis, N., De Gregorio, C., Tsigkas, G., Karu-nakaran, A., and Plotas, P. (2022). Pharmacologic Rate versus Rhythm Control for Atrial Fibrillation in Heart Failure Patients. Medicina, 58.","DOI":"10.3390\/medicina58060743"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00540-007-0573-3","article-title":"Clinical Role and Efficacy of Landiolol in the Intensive Care Unit","volume":"22","author":"Yoshida","year":"2008","journal-title":"J. Anesth."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1248\/cpb.40.1462","article-title":"Development of a Highly Cardioselective Ultra Short-Acting \u03b2-Blocker, ONO-1101","volume":"40","author":"Iguchi","year":"1992","journal-title":"Chem. Pharm. Bull."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2133\/dmpk.20.337","article-title":"Pharmacokinetics and Pharmacodynamics of Landiolol Hydrochloride, an Ultra Short-Acting \u03b21-Selective Blocker, in a Dose Escalation Regimen in Healthy Male Volunteers","volume":"20","author":"Murakami","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Levy, B., Slama, M., Lakbar, I., Maizel, J., Kato, H., Leone, M., and Okada, M. (2024). Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13102951"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13613-024-01418-8","article-title":"Comparison of the Efficacy and Safety of Landiolol and Esmolol in Critically Ill Patients: A Propensity Score-Matched Study","volume":"15","author":"Si","year":"2025","journal-title":"Ann. Intensive Care"},{"key":"ref_23","first-page":"840615","article-title":"Management of Atrial Fibrillation in Critically Ill Patients","volume":"2014","author":"Arrigo","year":"2014","journal-title":"Crit. Care Res. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1093\/eurheartj\/sux037","article-title":"Landiolol: Pharmacology and Its Use for Rate Control in Atrial Fibrillation in an Emergency Setting","volume":"20","author":"Domanovits","year":"2018","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_25","first-page":"293","article-title":"Incidence and Prognosis of Atrial Fibrillation in Patients with Sepsis","volume":"2","author":"Wells","year":"2011","journal-title":"Cardiol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131673","DOI":"10.1016\/j.ijcard.2023.131673","article-title":"Atrial Fibrillation and Survival on a Medical Intensive Care Unit","volume":"399","author":"Rottmann","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s13054-014-0688-5","article-title":"Incidence, Risk Factors and Outcomes of New-Onset Atrial Fibrillation in Patients with Sepsis: A Systematic Review","volume":"18","author":"Kuipers","year":"2014","journal-title":"Crit. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(07)61344-0","article-title":"Norepinephrine plus Dobutamine versus Epinephrine Alone for Management of Septic Shock: A Randomised Trial","volume":"370","author":"Annane","year":"2007","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMra1208943","article-title":"Circulatory Shock","volume":"369","author":"Vincent","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0735-1097(01)01587-X","article-title":"ACC\/AHA\/ESC Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guide-lines for the Management of Patients With Atrial Fibrillation)","volume":"38","author":"Fuster","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","article-title":"Efficacy and Safety of Landiolol, an Ultra-Short-Acting \u03921-Selective Antagonist, for Treatment of Sepsis-Related Tachyarrhythmia (J-Land 3S): A Multicentre, Open-Label, Randomised Controlled Trial","volume":"8","author":"Kakihana","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1253\/circj.CJ-11-1332","article-title":"Landiolol, an Ultra-Short-Acting \u03921-Blocker, More Effectively Terminates Atrial Fibrillation than Diltiazem after Open Heart Surgery: Prospective, Multicenter, Randomized, Open-Label Study (JL-KNIGHT Study)","volume":"76","author":"Sakamoto","year":"2012","journal-title":"Circ. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1007\/s12630-023-02586-0","article-title":"Landiolol for the Prevention of Postoperative Atrial Fibrillation after Cardiac Surgery: A Systematic Review and Meta-Analysis","volume":"70","author":"Cafaro","year":"2023","journal-title":"Can. J. Anaesth."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:48:46Z","timestamp":1760035726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091703"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091703","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}